
CDNA — CareDx Inc
NASDAQ · Healthcare · Diagnostics & Research
$48.87
-$0.10 (-0.21%)
CareDx Inc (CDNA) is a diagnostics & research company listed on NASDAQ. It is led by John Walter Hanna Jr., based in 8000 Marina Boulevard, Brisbane, CA, United States, 94005, with about 761 employees. CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Latest reported CDNA revenue for 2025-09-30 was $100.1M. Net income was $1.7M. Revenue was up 15.4% from 2025-06-30 to 2025-09-30. CDNA currently screens at market cap $1.18B.
Use this CDNA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CDNA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CDNA SEC filings page. Lician reads the product cache first so this HTML stays unique to CareDx Inc even when a live quote feed is slow.
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
CDNA Key Statistics
Market Cap
$1.18B
Volume
1.78M
Previous Close
$47.50
Day Range
$47.23 – $51.13
EPS
$0.93
Revenue
$333.79M
Net Income
$52.55M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+19.1%
Profit Margin
15.7%
Employees
761
CDNA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $333.79M | $280.32M | $321.79M | $296.40M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $52.55M | -$190.28M | -$76.61M | -$30.66M |
| EPS (Diluted) | $0.93 | -$3.54 | -$1.44 | -$0.59 |
Total Assets
$491.05M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$114.69M
Operating Cash Flow
$38.05M
Free Cash Flow
$0.00
CareDx Inc Company Information
- President, CEO & Director
- John Walter Hanna Jr.
- Headquarters
- 8000 Marina Boulevard, Brisbane, CA, United States, 94005
- Website
- caredx.com
- Phone
- 415 287 2300
- IPO / Founded
- 2014-07-17
- Sector
- Healthcare
- Industry
- Diagnostics & Research